Document Detail


INFLAMMATORY BIOMARKER CHANGES AND THEIR CORRELATION WITH FRAMINGHAM CARDIOVASCULAR RISK AND LIPID CHANGES IN ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS TREATED FOR 144 WEEKS WITH ABACAVIR/LAMIVUDINE/ATAZANAVIR WITH OR WITHOUT RITONAVIR IN ARIES.
MedLine Citation:
PMID:  23039030     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk factors and elevated inflammatory biomarkers. Cardiovascular risk and inflammatory biomarkers were evaluated in ARIES, a Phase IIIb/IV clinical trial in which 515 antiretroviral-naïve HIV-infected subjects initially received abacavir/lamivudine+atazanavir/ritonavir for 36 weeks. Subjects who were virologically suppressed by week 30 were randomized 1:1 at week 36 to either maintain or discontinue ritonavir for an additional 108 weeks. Framingham 10-year CHD risk scores (FRS) and risk category of <6% or 6%, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP) were assessed at baseline, week 84, and week 144. Biomarkers were stratified by FRS category. When ritonavir-boosted/non-boosted treatment groups were combined, median hsCRP did not change significantly between baseline (1.6mg/liter) and week 144 (1.4mg/liter) in subjects with FRS<6% (p=0.535), or with FRS6% (1.9mg/liter vs 2.0mg/liter, respectively; p=0.102). Median IL-6 was similar for subjects with FRS<6% (p=0.267) at baseline (1.6pg/ml) and week 144 (1.4 pg/ml) and for FRS6% (2.0pg/ml vs. 2.2pg/ml, respectively; p=0.099). Median Lp-PLA2 decreased significantly (p<0.001) between baseline (197 nmol/min/ml) and week 144 (168 nmol/min/ml) in subjects with FRS<6% and with FRS6% (238 nmol/min/ml vs. 175 nmol/min/ml, respectively; p<0.001). In conclusion, in antiretroviral-naïve subjects treated with abacavir-based therapy for 144 weeks, median inflammatory biomarker levels for hsCRP and IL-6 generally remained stable with no significant difference between baseline and week 144 for subjects with either FRS<6% or FRS6%. Lp-PLA2 median values declined significantly over 144 weeks for subjects in either FRS stratum.
Authors:
Benjamin Young; Kathleen Squires; Lisa Lynn Ross; Lizette Santiago; Louis M Sloan; Henry H Zhao; Brian C Wine; Gary Edward Pakes; David A Margolis; Mark S Shaefer
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  -     ISSN:  1931-8405     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Apex Research , 300 S. Jackson St, Suite 230, Denver, Colorado, United States, 80209; byoung@rockymountaincares.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structural insights into the function of the nicotinate mononucleotide:phenol/p-cresol phosphoribosy...
Next Document:  Prospective clinical audit of chloral hydrate administration practices in a neonatal unit.